PTD-DBM

PTD-DBM is a synthetic research peptide formed by joining a protein transduction domain (PTD) to a Dishevelled-binding motif (DBM). Researchers use this fusion peptide to study its interaction with the Wnt/beta-catenin signaling pathway. It is grouped with healing- and tissue-repair-related research compounds and is intended for laboratory research use only.

In plain terms, PTD-DBM is a lab-made peptide (a short chain of amino acids) built from the two segments described above. It belongs to a broader group of compounds researchers study for their role in cell-signaling research, particularly within the Wnt/beta-catenin pathway. It is supplied strictly for research use and is not FDA-approved.

PTD-DBM is typically supplied as a lyophilized powder in a sealed vial for research reconstitution. As with other lyophilized research materials, it should be brought to room temperature before reconstitution, and diluent should be added slowly along the vial wall rather than injected directly onto the powder, which helps preserve the integrity of the cake and minimizes foaming.

Reconstituted solution is generally stored refrigerated and used within the timeframe noted on your own protocol documentation, as lyophilized peptides and reconstituted solutions have different stability profiles. Standard aseptic technique - clean stoppers, single-use draws where possible, and correctly matched needle gauge - applies during reconstitution and transfer, the same as with any other lyophilized research compound handled in a lab setting.

What it is

PTD-DBM is a synthetic research peptide, a short chain of amino acids assembled from two joined segments:

• Protein transduction domain (PTD) - a sequence that lets the molecule cross a cell's outer membrane.
• Dishevelled binding motif (DBM) - a sequence that binds a specific intracellular protein called Dishevelled.

Together, these segments are studied for how they interact with the Wnt/beta-catenin signaling pathway, a network of cell-to-cell signals involved in growth and repair processes. In laboratory settings, PTD-DBM is used as a tool compound to probe how disrupting this interaction affects Wnt-pathway activity in cell-based models. It is intended strictly for research use, is not evaluated for human or animal administration, and no outcome claims are made about it.

Research context and categorization

Mechanism of Action

PTD-DBM is categorized within healing and tissue-repair research, with secondary overlap in skin and hair follicle research. In published cell and animal studies, PTD-DBM works by blocking a protein called CXXC5 from binding to Dishevelled (Dvl), an early component of the Wnt signaling pathway. CXXC5 normally functions as a negative regulator of Wnt signaling, and is itself induced by Wnt activity, forming a negative feedback loop.

By displacing CXXC5 from Dvl, PTD-DBM is reported to interrupt that feedback loop and remove the inhibitory brake, allowing Wnt signaling to proceed. This mechanism has been characterized in vitro and in animal models only, and researchers generally place PTD-DBM alongside other Wnt-pathway modulators rather than growth-factor or hormone-class peptides.

Preclinical Studies

Preclinical characterization of PTD-DBM spans several distinct research threads, summarized below:

• Pathway studied: Wnt/beta-catenin signaling
• Research focus: hair follicle biology and skin wound-healing models
• Source institution: research published by a group at Yonsei University
• Combination studies: some protocols pair PTD-DBM with valproic acid, a separate Wnt-pathway activator, to examine wound-induced follicle regeneration in animal models
• Study stage: preclinical only - conducted in cultured cells or animal subjects, not in people

As of this writing, there are no completed, peer-reviewed human clinical trials of PTD-DBM. Every mechanism and outcome described above comes from preclinical literature and is not confirmed, approved, or established for use in people. This section reflects current published research only and should not be interpreted as clinical guidance.

Key point: PTD-DBM is strictly an investigational, research-only peptide with no completed human trials or regulatory approval for clinical use.

Status

Status here refers only to PTD-DBM's regulatory and competitive-sport standing — not to hardware compatibility, handling, or ordering, which are covered elsewhere on this page.

• Regulatory status: PTD-DBM is a research compound. PreppinPeppers sells research hardware (pens, cartridges and bacteriostatic water) and does not sell PTD-DBM. It has not received approval from the FDA or any comparable regulatory body, and it carries no formal classification as a bulk drug substance. This listing does not authorize, imply, or support any clinical, veterinary, or personal application.
• Sport status: PTD-DBM does not appear by name on the WADA Prohibited List, the reference list of substances banned in organized sport. As an unapproved synthetic peptide, it falls under WADA's Class S0 (Non-Approved Substances) category, which prohibits any substance lacking regulatory approval, at all times, in every sport WADA governs.

Reconstitution notes (general)

Reconstitution means dissolving a dry powder in a liquid diluent to create a working solution for laboratory use. The resulting concentration is calculated by dividing the milligrams of material in the vial by the milliliters of diluent added.

For example, a 5 mg vial mixed with 2 mL of diluent gives a solution of 2.5 mg per mL. Work out any vial-and-volume combination with the calculator at peptide calculator.

Solution appearance and stability

• Color or clarity changes: Some reconstituted solutions shift in appearance over time — for example, a copper-peptide solution moving from blue toward clear. This is typically a sign of oxidation or breakdown of the dissolved material, not a packaging defect, and is a laboratory observation rather than a usage cue.
• Diluent composition: Common bacteriostatic diluents include a small percentage of benzyl alcohol as a preservative. Diluent choice, storage temperature, and elapsed time since mixing can all influence how long a reconstituted solution remains chemically stable for research purposes.

Dilution and handling notes (compound-specific)

Solubility and Formulation

PTD-DBM comes as a lyophilized powder. Lyophilized means freeze-dried: the moisture is removed so the compound stays stable on the shelf. It is commonly sold in vials of 1 mg, 2 mg, 5 mg, and 10 mg, and must be dissolved in liquid before use in a lab setting.

It is often made as a TFA salt, which pairs the compound with trifluoroacetic acid to help the powder dissolve more easily in water. Because of this, it usually dissolves in bacteriostatic water without anything extra added.

A modest amount of water per vial is the common approach, chosen to reach a workable concentration rather than a very concentrated stock.

Mixing Protocol

PTD-DBM contains a part that resists mixing with water (the hydrophobic transduction domain, similar to oil in water). This means some batches may dissolve slowly or look slightly cloudy if made too concentrated. Handle reconstitution carefully:

• Add the water gently down the inside wall of the vial rather than directly onto the powder.
• Let the vial sit and swirl slowly rather than shaking it.
• If a batch resists dissolving in plain water, a very small amount of DMSO (a solvent that helps water-resistant compounds dissolve) is sometimes used to pre-wet the powder before diluting into an aqueous buffer.
• Do not force dissolution by vigorous shaking or vortexing, as this can cause foaming or damage the peptide.

Some topical lab preparations in the literature use a water-plus-DMSO vehicle for this reason. Visible cloudiness or undissolved material signals a solubility limit, not a dosing cue.

Benzyl Alcohol and Solution Stability

Bacteriostatic water contains a small amount of benzyl alcohol as a preservative. Whether that affects a peptide's stability in solution varies by compound, concentration, and storage conditions — there's no single rule that covers every peptide. No independent third-party stability study using a benzyl-alcohol-preserved diluent has been published for PTD-DBM, so treat solvent choice as a variable to document in your own notes rather than assume it's neutral.

Handling and storage

Store the reconstituted solution in a refrigerator at 2 to 8 °C, away from direct light. Wipe the vial stopper with an alcohol swab before and after each use, and label the vial with the mix date.

A reconstituted solution is generally treated as usable for about 4 weeks under refrigeration. Keep dry powder cold before mixing, and never freeze a solution once reconstituted.

Diluent choice affects stability: bacteriostatic water containing benzyl alcohol can influence how some peptides hold up in solution over time, which is one reason mixed vials are treated as short-shelf-life items rather than stored indefinitely.

Color and clarity are simple visual checks. A shift from a tinted solution to clear, or the appearance of cloudiness or particles, generally signals degradation - discard the vial rather than continuing to use it.

Frequently asked questions